Search

Your search keyword '"Kapiteijn, Ellen W"' showing total 34 results
Start Over Author "Kapiteijn, Ellen W"
34 results on '"Kapiteijn, Ellen W"'

2. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

Author

van der Hiel, Bernies, Aalbersberg, Else A., van den Eertwegh, Alfons J.M., de Wit-van der Veen, Linda J., Stokkel, Marcel P.M., Lopez-Yurda, Marta, Boellaard, Ronald, Kapiteijn, Ellen W., Hospers, Geke A.P., Aarts, Maureen J.B., de Vos, Filip Y.F.L., Boers-Sonderen, Marye J., van der Veldt, Astrid A.M., de Groot, Jan Willem B., and Haanen, John B.A.G

Published
2024
Full Text
View/download PDF

3. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

4. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

Author

Bloem, Manja, van Not, Olivier J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers‐Sonderen, Marye J., Bonenkamp, Johannes J., de Groot, Jan‐Willem B., Haanen, John B., Hospers, Geke A. P., Kapiteijn, Ellen W., de Meza, Melissa M., Piersma, Djura, van Rijn, Rozemarijn S., Stevense‐den Boer, Marion A. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van den Eertwegh, Alfons J. M., and Suijkerbuijk, Karijn P. M.

Subjects
IMMUNE checkpoint inhibitors, IMMUNOLOGICAL adjuvants, OVERALL survival, REGRESSION analysis, MELANOMA
Abstract

Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti‐PD‐1 after complete resection. All stages III–IV AM and CM patients receiving adjuvant anti‐PD‐1 after complete resection between 2018 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence‐free survival (RFS), distant metastasis‐free survival (DMFS), and overall survival (OS). A multivariable Cox regression analysis of RFS was performed to adjust for potential confounders. We included 1958 (86 AM and 1872 CM) patients. At baseline, AM patients more frequently had KIT mutations, higher disease stages, and Eastern Cooperative Oncology Group Performance Status, and fewer BRAF and NRAS mutations. Median RFS was 14.8 months (95% confidence interval [CI]: 11.5–29.3) in AM and 37.4 months (95% CI: 34.6 to not reached) in CM (p =.002). After correcting for potential confounders, AM remained associated with a higher risk of recurrence (HRadj 1.53; 95% CI: 1.07–2.17; p =.019). Two‐year DMFS tended to be worse for AM than for CM: 64.5% versus 79.7% (p =.050). Two‐year OS was significantly lower in AM (71.5% vs. 84.3%; p =.027). The results of this study suggest a poorer outcome of adjuvant‐treated AM compared to CM. Studies assessing the added value of adjuvant treatment in AM are needed. Future research should investigate alternative treatment strategies to improve outcomes of high‐risk AM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

6. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

Author

MS Medische Oncologie, Brain, Cancer, van der Hiel, Bernies, Aalbersberg, Else A, van den Eertwegh, Alfons J M, de Wit-van der Veen, Linda J, Stokkel, Marcel P M, Lopez-Yurda, Marta, Boellaard, Ronald, Kapiteijn, Ellen W, Hospers, Geke A P, Aarts, Maureen J B, de Vos, Filip Y F L, Boers-Sonderen, Marye J, van der Veldt, Astrid A M, de Groot, Jan Willem B, Haanen, John B A G, MS Medische Oncologie, Brain, Cancer, van der Hiel, Bernies, Aalbersberg, Else A, van den Eertwegh, Alfons J M, de Wit-van der Veen, Linda J, Stokkel, Marcel P M, Lopez-Yurda, Marta, Boellaard, Ronald, Kapiteijn, Ellen W, Hospers, Geke A P, Aarts, Maureen J B, de Vos, Filip Y F L, Boers-Sonderen, Marye J, van der Veldt, Astrid A M, de Groot, Jan Willem B, and Haanen, John B A G

Published
2024

7. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

Author

van der Hiel, Bernies, primary, Aalbersberg, Else A., additional, van den Eertwegh, Alfons J.M., additional, de Wit-van der Veen, Linda J., additional, Stokkel, Marcel P.M., additional, Lopez-Yurda, Marta, additional, Boellaard, Ronald, additional, Kapiteijn, Ellen W., additional, Hospers, Geke A.P., additional, Aarts, Maureen J.B., additional, de Vos, Filip Y.F.L., additional, Boers-Sonderen, Marye J., additional, van der Veldt, Astrid A.M., additional, de Groot, Jan Willem B., additional, and Haanen, John B.A.G, additional

Published
2023
Full Text
View/download PDF

8. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

Author

van Zeijl, Michiel C.T., Haanen, John B.A.G., Wouters, Michel W.J.M., de Wreede, Liesbeth C., Jochems, Anouk, Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, van der Hoeven, Koos J.M., and van den Eertwegh, Alfons J.M.

Published
2020
Full Text
View/download PDF

9. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials

Author

de Meza, Melissa M., primary, Blokx, Willeke A. M., additional, Bonenkamp, Han J., additional, Blank, Cristian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers‐Sonderen, Marye J., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense‐Den Boer, Marion A., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, van den Eertwegh, Alfons J. M., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2023
Full Text
View/download PDF

10. ASO Visual Abstract:Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Blokx, Willeke A.M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J.M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W.J.M., van Akkooi, Alexander C.J., Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Blokx, Willeke A.M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J.M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W.J.M., and van Akkooi, Alexander C.J.

Published
2023

11. Adjuvant treatment of in-transit melanoma:Narrowing the knowledge gap left by clinical trials

Author

de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-Den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, Wouters, Michel W J M, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-Den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, and Wouters, Michel W J M

Abstract

Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyond clinical trials. In this study, we included stage III adjuvant-treated melanoma patients registered in the nationwide Dutch Melanoma Treatment Registry between July 2018 and December 2020. Patients were divided into three groups: nodal disease only, ITM only and ITM and nodal disease. Recurrence patterns, recurrence-free survival (RFS) and overall survival (OS) at 12-months were analyzed. In our study population of 1037 patients, 66.8% had nodal disease only, 16.7% had ITM only and 16.2% had ITM with nodal disease. RFS at 12-months was comparable in the nodal only and ITM only group (72.2% vs70.1%, P = .97) but lower in ITM and nodal disease patients (57.8%; P = .01, P < .01). Locoregional metastases occurred as first recurrence in 38.9% nodal disease only, 71.9% of ITM-only and 44.0% of ITM and nodal disease patients. Distant recurrences occurred in 42.3%, 18.8% and 36.0%, respectively (P = .02). 12-months OS was not significantly different for nodal disease only patients compared with ITM-only (94.4% vs 97.6%, P = .06) but was significantly higher for ITM-only compared with ITM and nodal disease patients (97.6% vs 91.0%, P < .01). In conclusion, we showed that in the adjuvant setting, RFS rates in ITM-only patients are similar to non-ITM, though better than in ITM and nodal disease patients. Adjuvant-treated ITM-only patients less often experience distant recurrences and have a superior OS compared with ITM and nodal disease patients.

Published
2023

12. Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, Wouters, Michel W J M, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M, Blokx, Willeke A M, Bonenkamp, Han J, Blank, Cristian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van den Eertwegh, Alfons J M, Suijkerbuijk, Karijn P M, and Wouters, Michel W J M

Published
2023

13. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, van Akkooi, Alexander C J, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2023

14. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, van Akkooi, Alexander C J, Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, Blankenstein, Stephanie A, Bonenkamp, Johannes J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Blokx, Willeke A M, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen W, van Not, Olivier J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Westgeest, Hans M, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2023

15. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., primary, Bonenkamp, Johannes J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Blokx, Willeke A. M., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfons J. M., additional, Franken, Margreet G., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Westgeest, Hans M., additional, Wouters, Michel W. J. M., additional, and van Akkooi, Alexander C. J., additional

Published
2022
Full Text
View/download PDF

16. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., primary, Bonenkamp, Johannes J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Blokx, Willeke A. M., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfons J. M., additional, Franken, Margreet G., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Westgeest, Hans M., additional, Wouters, Michel W. J. M., additional, and van Akkooi, Alexander C. J., additional

Published
2022
Full Text
View/download PDF

17. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

de Meza, Melissa M., primary, Ismail, Rawa K., additional, Rauwerdink, Daan, additional, van Not, Olivier J., additional, van Breeschoten, Jesper, additional, Blokx, Willeke A.M., additional, de Boer, Anthonius, additional, van Dartel, Maaike, additional, Hilarius, Doranne L., additional, Ellebaek, Eva, additional, Bonenkamp, Han J., additional, Blank, Christian U., additional, Aarts, Maureen J.B., additional, van Akkooi, Alexander C.J., additional, van den Berkmortel, Franchette W.P.J., additional, Boers-Sonderen, Marye J., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Hospers, Geke A.P., additional, Kapiteijn, Ellen W., additional, Piersma, Djura, additional, van Rijn, Roos S., additional, van der Veldt, Astrid A.M., additional, Vreugdenhil, Art, additional, Westgeest, Hans M., additional, van den Eertwegh, Alfons J.M., additional, Suijkerbuijk, Karijn P.M., additional, and Wouters, Michel W.J.M., additional

Published
2021
Full Text
View/download PDF

18. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Author

Kelderman, Sander, Heemskerk, Bianca, van Tinteren, Harm, van den Brom, Rob R. H., Hospers, Geke A. P., van den Eertwegh, Alfonsus J. M., Kapiteijn, Ellen W., de Groot, Jan Willem B., Soetekouw, Patricia, Jansen, Rob L., Fiets, Edward, Furness, Andrew J. S., Renn, Alexandra, Krzystanek, Marcin, Szallasi, Zoltan, Lorigan, Paul, Gore, Martin E., Schumacher, Ton N. M., Haanen, John B. A. G., Larkin, James M. G., and Blank, Christian U.

Published
2014
Full Text
View/download PDF

19. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

Author

Versluis, Judith M., primary, Hendriks, Anne M., additional, Weppler, Alison M., additional, Brown, Lauren J., additional, de Joode, Karlijn, additional, Suijkerbuijk, Karijn P.M., additional, Zimmer, Lisa, additional, Kapiteijn, Ellen W., additional, Allayous, Clara, additional, Johnson, Douglas B., additional, Hepner, Adriana, additional, Mangana, Joanna, additional, Bhave, Prachi, additional, Jansen, Yanina J.L., additional, Trojaniello, Claudia, additional, Atkinson, Victoria, additional, Storey, Lucy, additional, Lorigan, Paul, additional, Ascierto, Paolo A., additional, Neyns, Bart, additional, Haydon, Andrew, additional, Menzies, Alexander M., additional, Long, Georgina V., additional, Lebbe, Celeste, additional, van der Veldt, Astrid A.M., additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, van Tinteren, Harm, additional, de Vries, Elisabeth G.E., additional, Blank, Christian U., additional, and Jalving, Mathilde, additional

Published
2021
Full Text
View/download PDF

20. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A., primary, Bastiaannet, Esther, additional, van den Bos, Frederiek, additional, Mooijaart, Simon P., additional, van der Veldt, Astrid A. M., additional, Suijkerbuijk, Karlijn P. M., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan-Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Jalving, Hilde, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, ten Tije, Albert J., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Portielje, Johanneke E. A., additional, and Kapiteijn, Ellen W., additional

Published
2021
Full Text
View/download PDF

21. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021

22. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, Kapiteijn, Ellen W, de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, and Kapiteijn, Ellen W

Abstract

BACKGROUND: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and outcomes of "real-world" older patients with metastatic melanoma and to identify predictors of outcome.METHODS: We included patients aged ≥65 years with metastatic melanoma from the Dutch Melanoma Treatment Registry. We described the reasons for hospital admissions and treatment discontinuation. Additionally, we assessed predictors of toxicity and response using logistic regression models and survival using Cox regression models.RESULTS: We included 2216 patients. Grade ≥3 toxicity was not associated with age, comorbidities or WHO status. Patients aged ≥75 discontinued treatment due to toxicity more often, resulting in fewer treatment cycles. Response rates were similar to previous trials (40.3% and 43.6% in patients aged 65-75 and ≥75, respectively, for anti-PD1 treatment) and did not decrease with age or comorbidity. Melanoma-specific survival was not affected by age or comorbidity.CONCLUSION: Response rates and toxicity outcomes of checkpoint inhibitors did not change with increasing age or comorbidity. However, the impact of grade I-II toxicity on quality of life deserves further study as older patients discontinue treatment more frequently.

Published
2021

23. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Abstract

Background: Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality and safety of melanoma care in the Netherlands. This study aims to describe treatment patterns, relapse, and toxicity rates of adjuvant-treated melanoma patients beyond the clinical trial setting. Methods: Analyses were performed on adjuvant-treated melanoma patients included in the DMTR. Descriptive statistics were used to analyse patient-, and treatment characteristics. A baseline registration completeness analysis was performed, and an analysis on trial eligibility in clinical practice patients. Recurrence-free survival (RFS) at 12-months was estimated with the Kaplan–Meier method. Results: A total of 641 patients were treated with adjuvant anti-PD-1 therapy. RFS at 12-months was 70.6% (95% CI, 66.9–74.6) with a median follow-up of 12.8 months. Sex, stage of disease and Breslow thickness were associated with a higher hazard for RFS. Eighteen per cent of the anti-PD-1-treated patients developed grade ≥3 toxicity. Sixty-one per cent of patients prematurely discontinued anti-PD-1 therapy. Conclusion: Adjuvant anti-PD-1 treatment of resected stage III/IV melanoma in daily practice showed slightly higher toxicity rates and more frequent premature discontinuation but similar RFS rates compared to trials.

Published
2021

24. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition:A multicentre retrospective analysis

Author

Versluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E., Blank, Christian U., Jalving, Mathilde, Versluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E., Blank, Christian U., and Jalving, Mathilde

Abstract

Introduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma. Patients and methods: Patients with metastatic melanoma treated with ICI between 2010 and 2019 with solitary progression as first progressive event were included from 17 centres in 9 countries. Follow-up and survival are reported from ICI initiation. Results: We identified 294 patients with solitary progression after stable disease in 15%, partial response in 55% and complete response in 30%. The median follow-up was 43 months; the median time to solitary progression was 13 months, and the median time to subsequent progression after treatment of solitary progression (TTSP) was 33 months. The estimated 3-year overall survival (OS) was 79%; median OS was not reached. Treatment consisted of systemic therapy (18%), local therapy (36%), both combined (42%) or active surveillance (4%). In 44% of patients treated for solitary progression, no subsequent progression occurred. For solitary progression during ICI (n = 143), the median TTSP was 29 months. Both TTSP and OS were similar for local therapy, ICI continuation and both combined. For solitary progression post ICI (n = 151), the median TTSP was 35 months. TTSP was higher for ICI recommencement plus local therapy than local therapy or ICI recommencement alone (p = 0.006), without OS differences. Conclusion: Almost half of patients with melanoma treated for solitary progression after initial response to ICI had no subsequent progression. This study suggests that local therapy can benefit patients and is associated with favourable long-term outcomes.

Published
2021

25. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity, de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021

26. Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors†

Author

MS Medische Oncologie, Infection & Immunity, Cancer, de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A.M., Suijkerbuijk, Karlijn P.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., Ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Portielje, Johanneke E.A., Kapiteijn, Ellen W., MS Medische Oncologie, Infection & Immunity, Cancer, de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A.M., Suijkerbuijk, Karlijn P.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., Ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Portielje, Johanneke E.A., and Kapiteijn, Ellen W.

Published
2021

27. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Versluis, Judith M, Hendriks, Anne M, Weppler, Alison M, Brown, Lauren J, de Joode, Karlijn, Suijkerbuijk, Karijn P M, Zimmer, Lisa, Kapiteijn, Ellen W, Allayous, Clara, Johnson, Douglas B, Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J L, Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A, Neyns, Bart, Haydon, Andrew, Menzies, Alexander M, Long, Georgina V, Lebbe, Celeste, van der Veldt, Astrid A M, Carlino, Matteo S, Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G E, Blank, Christian U, Jalving, Mathilde, MS Medische Oncologie, Infection & Immunity, Cancer, Versluis, Judith M, Hendriks, Anne M, Weppler, Alison M, Brown, Lauren J, de Joode, Karlijn, Suijkerbuijk, Karijn P M, Zimmer, Lisa, Kapiteijn, Ellen W, Allayous, Clara, Johnson, Douglas B, Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J L, Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A, Neyns, Bart, Haydon, Andrew, Menzies, Alexander M, Long, Georgina V, Lebbe, Celeste, van der Veldt, Astrid A M, Carlino, Matteo S, Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G E, Blank, Christian U, and Jalving, Mathilde

Published
2021

28. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van Zeijl, Michiel C T, Haanen, John B A G, Wouters, Michel W J M, de Wreede, Liesbeth C, Jochems, Anouk, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen W, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van der Hoeven, Koos J M, van den Eertwegh, Alfons J M, MS Medische Oncologie, Infection & Immunity, Cancer, van Zeijl, Michiel C T, Haanen, John B A G, Wouters, Michel W J M, de Wreede, Liesbeth C, Jochems, Anouk, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen W, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van der Hoeven, Koos J M, and van den Eertwegh, Alfons J M

Published
2020

29. Comprehensive analysis of cutaneous and uveal melanoma liver metastases

Author

Hoefsmit, Esmee P, primary, Rozeman, Elisa A, additional, Van, Trieu My, additional, Dimitriadis, Petros, additional, Krijgsman, Oscar, additional, Conway, Jordan W, additional, Pires da Silva, Ines, additional, van der Wal, Jacqueline E, additional, Ketelaars, Steven L C, additional, Bresser, Kaspar, additional, Broeks, Annegien, additional, Kerkhoven, Ron M, additional, Reeves, Jason W, additional, Warren, Sarah, additional, Kvistborg, Pia, additional, Scolyer, Richard A, additional, Kapiteijn, Ellen W, additional, Peeper, Daniel S, additional, Long, Georgina V, additional, Schumacher, Ton N M, additional, and Blank, Christian U, additional

Published
2020
Full Text
View/download PDF

31. Conjunctival Metastasis of a Cutaneous Melanoma

Author

Brouwer, Niels J., primary, Marinkovic, Marina, additional, Jochems, Anouk, additional, Kapiteijn, Ellen W., additional, van Duinen, Sjoerd G., additional, Haeseker, Barbara I., additional, Jager, Martine J., additional, and Luyten, Gregorius P.M., additional

Published
2017
Full Text
View/download PDF

32. Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients

Author

van Dijk, Elon H C, Duits, Danique E M, Versluis, Mieke, Luyten, Gregrorius P M, Bergen, Arthur A B, Kapiteijn, Ellen W, de Lange, Mark J, Boon, Camiel J F, van der Velden, Pieter A, van Dijk, Elon H C, Duits, Danique E M, Versluis, Mieke, Luyten, Gregrorius P M, Bergen, Arthur A B, Kapiteijn, Ellen W, de Lange, Mark J, Boon, Camiel J F, and van der Velden, Pieter A

Abstract

Recently, treatment with MEK inhibitors has been shown to be an effective treatment option for metastatic melanoma. Treatment efficacy is dependent on inhibition of MAPK-related melanoma proliferation. However, targeting of MEK can be accompanied by a time-dependent and reversible serous retinopathy of unknown origin.We analyzed the molecular mechanism by which the MEK inhibitor binimetinib may lead to retinopathy, using neuroretina and cell models of retinal pigment epithelium (RPE).Binimetinib inhibited the MAPK pathway while discontinuation of treatment resulted in reactivation. However, cell proliferation was not inhibited correspondingly during binimetinib treatment of ARPE19 cells. Remarkably, post-mitotic neuroretinal tissue displayed a strong MAPK activation that was lost after binimetinib treatment.We propose that binimetinib-associated retinopathy is correlated with inhibition of the MAPK pathway in multiple retinal components. Retinal cells are able to regain the activation after binimetinib treatment, mimicking the reversibility of the retinopathy. As most retinal cells are nonregenerating, other mechanisms than stimulation of proliferation must be involved.

Published
2016

34. Conjunctival Metastasis of a Cutaneous Melanoma

Author

Brouwer, Niels J., Marinkovic, Marina, Jochems, Anouk, Kapiteijn, Ellen W., van Duinen, Sjoerd G., Haeseker, Barbara I., Jager, Martine J., and Luyten, Gregorius P.M.

Abstract

Purpose:To report a patient who presented with a conjunctival tumour as a first sign of distant metastasis of cutaneous melanoma. The patient was treated successfully with BRAF/MEK-inhibitors and anti-PD-1 antibodies. Methods:Clinical and histopathological examination of the conjunctival lesion. Results:A 74-year-old man was referred to our hospital with a pigmented conjunctival tumour, 5 months after having been diagnosed with cutaneous melanoma on his right scapula with loco-regional axillary lymph node metastases. The conjunctival lesion was excised and showed a BRAF V600E mutation. Histopathology showed a melanoma with characteristics suspicious for metastasis, as the lesion did not have a relation with the overlying epithelium. Systemic screening showed multiple distant metastases of the cutaneous melanoma in spleen, liver, and bone. Systemic treatment with the combination of a BRAF-inhibitor (dabrafenib) and MEK-inhibitor (trametinib) was started and followed by a switch to an anti-PD-1 antibody (pembrolizumab). Twenty-two months later, the patient is alive and in good clinical health. Conclusion:Conjunctival metastases of cutaneous melanoma may mimic primary conjunctival melanoma. A good medical history and systemic work-up are required to differentiate these diseases. Identification of the proper diagnosis including mutation analysis is crucial, allowing patients to benefit from newly introduced treatment strategies for metastatic cutaneous melanoma.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results